BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Campos MA, Geraghty P, Holt G, Mendes E, Newby PR, Ma S, Luna-Diaz LV, Turino GM, Stockley RA. The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial. Am J Respir Crit Care Med 2019;200:318-26. [PMID: 30965011 DOI: 10.1164/rccm.201901-0010OC] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 14.5] [Reference Citation Analysis]
Number Citing Articles
1 Chen YH, Cheadle CE, Rice LV, Pfeffer PE, Dimeloe S, Gupta A, Bush A, Gooptu B, Hawrylowicz CM. The Induction of Alpha-1 Antitrypsin by Vitamin D in Human T Cells Is TGF-β Dependent: A Proposed Anti-inflammatory Role in Airway Disease. Front Nutr 2021;8:667203. [PMID: 34458299 DOI: 10.3389/fnut.2021.667203] [Reference Citation Analysis]
2 Wettstein L, Weil T, Conzelmann C, Müller JA, Groß R, Hirschenberger M, Seidel A, Klute S, Zech F, Prelli Bozzo C, Preising N, Fois G, Lochbaum R, Knaff PM, Mailänder V, Ständker L, Thal DR, Schumann C, Stenger S, Kleger A, Lochnit G, Mayer B, Ruiz-Blanco YB, Hoffmann M, Sparrer KMJ, Pöhlmann S, Sanchez-Garcia E, Kirchhoff F, Frick M, Münch J. Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection. Nat Commun 2021;12:1726. [PMID: 33741941 DOI: 10.1038/s41467-021-21972-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
3 McKelvey MC, Brown R, Ryan S, Mall MA, Weldon S, Taggart CC. Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease. Int J Mol Sci 2021;22:5018. [PMID: 34065111 DOI: 10.3390/ijms22095018] [Reference Citation Analysis]
4 Ke H, Guay KP, Flotte TR, Gierasch LM, Gershenson A, Hebert DN. Secretion of functional α1-antitrypsin is cell type dependent: Implications for intramuscular delivery for gene therapy. Proc Natl Acad Sci U S A 2022;119:e2206103119. [PMID: 35901208 DOI: 10.1073/pnas.2206103119] [Reference Citation Analysis]
5 Dummer J, Dobler CC, Holmes M, Chambers D, Yang IA, Parkin L, Smith S, Wark P, Dev A, Hodge S, Dabscheck E, Gooi J, Samuel S, Knowles S, Holland AE. Diagnosis and treatment of lung disease associated with alpha one-antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand. Respirology 2020;25:321-35. [PMID: 32030868 DOI: 10.1111/resp.13774] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Martini F, De Mattei M, Contini C, Tognon MG. Potential Use of Alpha-1 Anti-trypsin in the Covid-19 Treatment. Front Cell Dev Biol 2020;8:577528. [PMID: 33195215 DOI: 10.3389/fcell.2020.577528] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Santos G, Turner AM. Alpha-1 antitrypsin deficiency: an update on clinical aspects of diagnosis and management. Fac Rev 2020;9:1. [PMID: 33659933 DOI: 10.12703/b/9-1] [Reference Citation Analysis]
8 Voynow JA, Shinbashi M. Neutrophil Elastase and Chronic Lung Disease. Biomolecules 2021;11:1065. [PMID: 34439732 DOI: 10.3390/biom11081065] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Viglio S, Iadarola P, D'Amato M, Stolk J. Methods of Purification and Application Procedures of Alpha1 Antitrypsin: A Long-Lasting History. Molecules 2020;25:E4014. [PMID: 32887469 DOI: 10.3390/molecules25174014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Campos MA, Geraghty P. Cytokine Regulation by Alpha-1 Antitrypsin Therapy: A Pathway Analysis of a Pilot Clinical Trial. Am J Respir Cell Mol Biol 2022;66:697-700. [PMID: 35648091 DOI: 10.1165/rcmb.2021-0503LE] [Reference Citation Analysis]
11 Mornex JF, Balduyck M, Bouchecareilh M, Cuvelier A, Epaud R, Kerjouan M, Le Rouzic O, Pison C, Plantier L, Pujazon MC, Reynaud-Gaubert M, Toutain A, Trumbic B, Willemin MC, Zysman M, Brun O, Campana M, Chabot F, Chamouard V, Dechomet M, Fauve J, Girerd B, Gnakamene C, Lefrançois S, Lombard JN, Maitre B, Maynié-François C, Moerman A, Payancé A, Reix P, Revel D, Revel MP, Schuers M, Terrioux P, Theron D, Willersinn F, Cottin V, Mal H. [French clinical practice guidelines for the diagnosis and management of lung disease with alpha 1-antitrypsin deficiency]. Rev Mal Respir 2022:S0761-8425(22)00233-9. [PMID: 35906149 DOI: 10.1016/j.rmr.2022.06.002] [Reference Citation Analysis]
12 Rahaghi FF. Alpha-1 antitrypsin deficiency research and emerging treatment strategies: what's down the road? Ther Adv Chronic Dis 2021;12_suppl:20406223211014025. [PMID: 34408832 DOI: 10.1177/20406223211014025] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Barjaktarevic I, Miravitlles M. Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis. BMC Pulm Med 2021;21:99. [PMID: 33757485 DOI: 10.1186/s12890-021-01466-x] [Reference Citation Analysis]
14 Wang C, Zhao P, Sun S, Teckman J, Balch WE. Leveraging Population Genomics for Individualized Correction of the Hallmarks of Alpha-1 Antitrypsin Deficiency. Chronic Obstr Pulm Dis 2020;7:224-46. [PMID: 32726074 DOI: 10.15326/jcopdf.7.3.2019.0167] [Reference Citation Analysis]
15 Chukowry PS, Edgar RG, Turner AM. Alpha 1 antitrypsin deficiency: a rare multisystem disease, predominantly affecting the lung. Expert Opinion on Orphan Drugs 2019;7:315-26. [DOI: 10.1080/21678707.2019.1651640] [Reference Citation Analysis]
16 Barrecheguren M, O'Hara K, Wilkens M, Boyd J, Kolda E, Lara B, Chorostowska-Wynimko J, Ferrarotti I, Chlumský J, Clarenbach C, Greulich T, Miravitlles M, Sucena M. Research priorities in α1-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration. ERJ Open Res 2020;6:00523-2020. [PMID: 33447613 DOI: 10.1183/23120541.00523-2020] [Reference Citation Analysis]
17 O'Brien ME, Fee L, Browne N, Carroll TP, Meleady P, Henry M, McQuillan K, Murphy MP, Logan M, McCarthy C, McElvaney OJ, Reeves EP, McElvaney NG. Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency. Thorax 2020;75:321-30. [PMID: 31959730 DOI: 10.1136/thoraxjnl-2019-214076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
18 O'Brien ME, Murray G, Gogoi D, Yusuf A, McCarthy C, Wormald MR, Casey M, Gabillard-Lefort C, McElvaney NG, Reeves EP. A Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic Application. Int J Mol Sci 2022;23:2441. [PMID: 35269582 DOI: 10.3390/ijms23052441] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Hawkins P, McEnery T, Gabillard-Lefort C, Bergin DA, Alfawaz B, Shutchaidat V, Meleady P, Henry M, Coleman O, Murphy M, McElvaney NG, Reeves EP. In vitro and in vivo modulation of NADPH oxidase activity and reactive oxygen species production in human neutrophils by α1-antitrypsin. ERJ Open Res 2021;7:00234-2021. [PMID: 34881324 DOI: 10.1183/23120541.00234-2021] [Reference Citation Analysis]
20 Crossley D, Stockley R, Sapey E. Alpha-1 Antitrypsin Deficiency and Accelerated Aging: A New Model for an Old Disease? Drugs Aging 2019;36:823-40. [PMID: 31179525 DOI: 10.1007/s40266-019-00684-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 McElvaney OJ, O'Connor E, McEvoy NL, Fraughan DD, Clarke J, McElvaney OF, Gunaratnam C, O'Rourke J, Curley GF, McElvaney NG. Alpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19. J Cyst Fibros 2021;20:31-5. [PMID: 33288475 DOI: 10.1016/j.jcf.2020.11.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Schouten IGM, Kasteleyn MJ, Tsonaka R, Bals R, Turner AC, Ferrarotti I, Corsico AG, Lara B, Miravitlles M, Stockley RA, Stolk J. Long-term effect of α1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients: an analysis of the AIR database. ERJ Open Res 2021;7:00194-2021. [PMID: 34435030 DOI: 10.1183/23120541.00194-2021] [Reference Citation Analysis]
23 Schouten IGM, Mumford RA, Moes DJAR, Hiemstra PS, Stolk J. The Course of AαVal541 as a Proteinase 3 Specific Neo-Epitope after Alpha-1-Antitrypsin Augmentation in Severe Deficient Patients. Int J Mol Sci 2021;22:8031. [PMID: 34360796 DOI: 10.3390/ijms22158031] [Reference Citation Analysis]
24 Barjaktarevic I, Campos M. Management of lung disease in alpha-1 antitrypsin deficiency: what we do and what we do not know. Ther Adv Chronic Dis 2021;12_suppl:20406223211010172. [PMID: 34408831 DOI: 10.1177/20406223211010172] [Reference Citation Analysis]
25 Ostermann L, Maus R, Stolper J, Schütte L, Katsarou K, Tumpara S, Pich A, Mueller C, Janciauskiene S, Welte T, Maus UA. Alpha-1 antitrypsin deficiency impairs lung antibacterial immunity in mice. JCI Insight 2021;6:140816. [PMID: 33554955 DOI: 10.1172/jci.insight.140816] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Segal L, Lewis EC. The Lipid Ties of α1-antitrypsin: Structural and Functional Aspects. Cellular Immunology 2022. [DOI: 10.1016/j.cellimm.2022.104528] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]